Archive · 17 Sep 2025
Ozempic's Risks: Lawsuits, Warnings, and Market Battles
Ozempic, a popular drug for diabetes and weight loss, has caused some patients serious problems.
People are suing the drug company, Novo Nordisk, claiming the drug caused stomach paralysis and vision loss.
Doctors are reminding us that while Ozempic helps many, it can also cause nausea and, rarely, more serious issues.
Regulators are adding warnings, and there are battles over the drug's patents and affordability.
The drug is like a medicine that helps a lot of people, but needs close monitoring due to potential risks.
Ozempic is facing lawsuits over side effects like stomach paralysis and vision loss.
Over 1,000 lawsuits have been consolidated in U.S. federal court.
Doctors note potential side effects, but emphasize most are manageable.
Regulators are issuing stronger warnings about side effects of Ozempic.
Novo Nordisk is involved in patent disputes over its active ingredient.
- Who
- Patients, Novo Nordisk, Dr. Kesava Reddy Mannur, Dr. Y. Jatin, Dr. Reddy’s Laboratories
- What
- Ozempic, a GLP-1 receptor agonist, faces lawsuits and regulatory scrutiny.
- When
- Ongoing, with legal cases and regulatory updates.
- Where
- U.S., India, and Europe
- Why
- To treat diabetes and aid weight loss, but concerns arise about side effects.
Patient Concerns
Company's Stance
Safety
Patient Concerns
Patients are experiencing severe side effects and seeking legal recourse.
Company's Stance
Novo Nordisk's perspective, emphasizing it is safe for most.
Access and Cost
Patient Concerns
High cost makes access more limited.
Company's Stance
Efforts to maintain market control hinder availability of affordable generic medicines.
- Drug Name
- Ozempic (semaglutide)
- Manufacturer
- Novo Nordisk
- Reported Side Effects
- Gastroparesis, vision loss, intestinal issues
- Lawsuits
- Over 1,000 filed in U.S.
- FDA Warnings
- Gastric emptying, obstruction, anesthesia risks
- Sales (2024)
- Over $20 billion
Sources
Will legal troubles in the US weigh on India’s obesity drug boom?
Lilly's Obesity Pill Will Have Far-Reaching Effect, Doctors Say
WHO’s new guidelines support weight-loss drugs from Novo Nordisk, Eli Lilly to treat obesity
Eli Lilly’s weight-loss trial shows average 12.4kg weight loss in 72 weeks